SD-SAB-BIO/CSL-BEHRING
7.1.2020 15:38:13 CET | Business Wire | Press release
SAB Biotherapeutics (SAB), a clinical-stage biopharmaceutical development company advancing a new class of immunotherapies, today announced that it has entered into multiple collaboration and option agreements with global biotherapeutics leader CSL Behring. The collaborations will explore the possibility and the potential of new therapies to treat challenging autoimmune, infectious and idiopathic diseases by leveraging SAB’s DiversitAb™ platform.
SAB has developed a unique platform, through advanced genetic engineering, to naturally and rapidly produce large amounts of human antibodies without using human donors.
The agreement includes a research program which will investigate a potential new source for human immunoglobulin G (IgG). Human IgG is currently used for a number of immunological and neurological diseases including Primary Immunodeficiency, Chronic Inflammatory Demyelinating Polyneuropathy (CIDP), Guillain-Barre Syndrome (GBS), Immune Thrombocytopenic Purpura (ITP), and Multifocal Motor Neuropathy (MMN).
CSL Behring is a leader in the global immunoglobulins market, which has grown substantially over the last five years. Key factors fueling market growth include an aging population, increased emphasis on the diagnosis and treatment of immune diseases, and its increased use in new indications.
“SAB Biotherapeutics has developed a very interesting and novel platform for the production of human immunoglobulins,” said Dr. Andrew Nash, Senior Vice President, Research for CSL Behring. “CSL Behring is committed to the continuous development of innovative therapies that address unmet needs for patients with rare and serious diseases. This collaboration will provide both companies an opportunity to explore the potential of these new approaches to positively impact areas of need.”
CSL Behring’s R&D footprint includes more than 1,700 scientists across the globe with an R&D investment exceeding $800 million in 2018 - 2019.
“We are excited that CSL Behring has chosen to work with SAB Biotherapeutics to explore new immunotherapies leveraging our technology platform,” said Dr. Eddie J. Sullivan, president, CEO and co-founder of SAB Biotherapeutics. “We believe combining our unique human antibody development and production capabilities with CSL Behring’s established immunoglobulin franchise and vast expertise in biopharmaceutical development will broaden therapeutic possibilities.”
CSL Behring and SAB will share research program and related costs and plan to complete the initial phase in 2020. The collaboration may lead to subsequent development and commercialization agreements.
About SAB Biotherapeutics, Inc.
SAB Biotherapeutics, Inc. (SAB), headquartered in Sioux Falls, S.D. is a clinical-stage, biopharmaceutical development company advancing a new class of immunotherapies leveraging fully human polyclonal antibodies. Utilizing some of the most complex genetic engineering and antibody science in the world, SAB has developed the only platform that can rapidly produce natural, highly targeted, high-potency, immunotherapies at commercial scale. The company is advancing programs in autoimmunity, infectious diseases, inflammation and exploratory oncology.
View source version on businesswire.com: https://www.businesswire.com/news/home/20200107005718/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
SLB OneSubsea Awarded Integrated EPC Contract for Deepwater Development17.3.2026 13:30:00 CET | Press release
Award adds to OneSubsea’s project pipeline and reinforces its standardized system design Global energy technology company SLB (NYSE: SLB) announced today that its OneSubsea™ joint venture has been awarded a multi-well, integrated engineering, production, and construction (EPC) contract by China National Offshore Oil Corporation (CNOOC). The contract encompasses 20 wells and covers the delivery of integrated subsea production systems for the deepwater Kaiping 18-1 field development in the South China Sea. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260317076557/en/ SLB OneSubsea will deliver standardized subsea production technology that includes dual electric submersible pump (ESP), gas lift and gas injection horizontal trees, manifolds, connectors, and control systems, along with installation and commissioning support. Under the contract, SLB OneSubsea will deliver standardized subsea production technology that includes
HyperLight Introduces 400G-per-lane TFLN PICs on its Chiplet™ Platform for Next-Generation AI Interconnects17.3.2026 13:03:00 CET | Press release
HyperLight Corporation (“HyperLight”), creator of the TFLN Chiplet™ Platform, today announced the availability of 400G-per-lane thin-film lithium niobate (TFLN) photonic integrated circuits (PICs) designed for next-generation AI networking infrastructure. The new PIC family delivers low insertion loss, low drive voltage operation, and exceptional electro-optic bandwidth, enabling energy-efficient and high-performance 400G-per-lane optical links. The transition to 400G-per-lane is a critical step for future AI infrastructure, enabling higher interconnect bandwidth and improved system density. HyperLight’s 400G-per-lane TFLN PICs provide the large electro-optic bandwidth and low-voltage operation required to support these next-generation optical links, where bandwidth, signal integrity, and power efficiency are increasingly challenging for electronic ICs to sustain. HyperLight’s TFLN devices combine high modulation efficiency with extremely low optical loss, enabling transmitter architec
Klarna Smashes 1 Million Merchants Milestone17.3.2026 13:00:00 CET | Press release
Klarna, the global digital bank and flexible payments provider, has surpassed 1 million merchants globally. Klarna has grown the number of merchants offering its payment methods by 47% in the past year, adding 285,000 merchants in 2025, and more than 115,000 in the final quarter alone. The growth is being driven by Klarna's expanding agreements with the world's leading payment service providers, giving merchants around the world easier access to Klarna at checkout. Leisure, Sport & Hobby is now Klarna's fastest-growing merchant category, up 91% YoY in February 2026, reflecting growing consumer demand for flexible payments in wellness and fitness. David Sykes, Chief Commercial Officer at Klarna: "Home repairs, a new couch, salon appointments, gym memberships - these are facts of life for most people, but the way they pay for them hasn't kept up. Reaching 1 million merchants is a reflection of how deeply embedded Klarna is becoming in everyday money management, and the acceleration acros
Armis Warns Cyberwarfare Threats at Global Tipping Point as AI Accelerates Escalation17.3.2026 13:00:00 CET | Press release
65% of IT decision-makers believe the convergence of AI, quantum, and emerging technologies will drive unprecedented escalation in cyber conflict Half of respondents say cyberwarfare threat is imminent and have had to report an act of cyberwarfare to authorities Armis, the cyber exposure management & security company, is warning that cyberwarfare threats have reached a global pressure-cooker moment. As emerging technologies accelerate cyber operations and geopolitical tensions worsen, attackers are increasingly targeting the infrastructure, information, and systems that underpin global stability. “Geopolitical tensions, AI acceleration, and unresolved security gaps are colliding, bringing the state of cyberwarfare to a boiling point,” said Nadir Izrael, CTO and Co-Founder of Armis. “Cyberwarfare is now a constant condition; attackers are operating at machine speed, while too many organizations are still trying to defend themselves with assumptions and structures built for a very differ
1.5 Billion Women Miss Essential Preventive Tests, Despite Uptick in Global Screening Rates17.3.2026 13:00:00 CET | Press release
Fifth edition of Hologic Global Women’s Health Index reveals over half of women worldwide weren’t tested for key conditions in the past yearHologic and Gallup convene experts to discuss closing gaps in screening access Global women’s health leader Hologic, Inc. (Nasdaq: HOLX) today released data showing that while testing for some health conditions has risen among women globally, a vast screening gap remains. Over half of women and girls aged 15 and older — an estimated 1.5 billion women — were not tested for cancer, high blood pressure, diabetes or sexually transmitted infections (STIs) in the past year. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260317786907/en/ Hologic Global Women's Health Index Fifth Edition The data are part of the fifth edition of the Hologic Global Women’s Health Index developed in partnership with Gallup. Based on an annual survey of 145,000 people in 144 countries and territories, the Index tra
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom